Histone Deacetylase (HDAC) Inhibitors Market & Pipeline Insight 2015
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Histone Deacetylase (HDAC) are enzymes responsible for removal of acetyl groups present on acetyl lysine amino acid attached to histone. They are responsible for gene expression and regulation which is responsible for cellular functioning. It also helps in wrapping of histone over the Deoxyribonucleic acid (DNA). They are involved in cell growth and death which is responsible for maintaining steady state. Their involvement in diseases has been noted by investigators due to which they could serve as lead molecule for drug development. Development of HDAC based therapeutics is correlated to the development of HDAC inhibitors which have capacity to inhibit HDACs which have gone under abnormal changes. Some of the HDAC inhibitors has been successfully commercialized in global market for different ailments.
HDAC inhibitors are being developed for different malignancies and some of these products have been in global market for more than decade. New products for different diseases are being introduced in market. Most of them have been developed for oncological application while few products have been introduced in neurology category. Investigational HDAC inhibitors are being developed for HIV, autoimmune, inflammatory disease and other ailments. Potential of HDAC inhibitors in animal models for inflammatory bowel diseases, diabetes, multiple sclerosis, age related macular degeneration, cardiovascular diseases and other diseases have been shown. HDAC inhibitors clinical pipeline is becoming strong as investment in their research and development is increasing. Various products are at different stages of clinical trials which would be introduced in coming years.
HDAC inhibitor market for cancer treatment for hematological malignancies and that to for lymphoma is quite competitive. Besides, Vorinostat and Istodax there is another drug for lymphoma called Beleodaq is available in this segment. Beleodaq is a novel pan HDAC inhibitor for treatment of fast-growing type of Non-Hodgkin Lymphoma (NHL)and Peripheral T-Cell Lymphoma (PTCL). It is expected that due to similar mechanism they will offer competition to each other in coming years. Competition is also expected to be offered by monoclonal antibodies which are already known for their superior pharmacological efficacy. In this scenario, HDAC inhibitor developers have to improve drug design and pharmacological profiles in order to survive in this market segment. Their costs are somewhat lesser then monoclonal antibodies due to which patients belonging to different financial background are expected to choose them as part of their therapeutic regime.
Novel HDAC inhibitors are also being discovered by investigators but their pharmacological and commercialization potential remains elusive. Some of them are already established in global market and others are being revisited for their therapeutics efficacy in other disease segments. Hydroxamates are one of the largest segment of HDAC inhibitors which have made their niche in cancer market segment. Other categories are also being developed for different ailments due to their role in blocking different HDAC members. It could be observed that they belong to different biological groups like aliphatic acids and cyclopeptides. On the other hand, synthetic derivatives are also available which could be easily modified by chemical processes. This fact shows that investigators have plethora of choices that will help them in development of suitable pharmaceutical product having high commercialization potential. However, lots of work is required in this segment for occupying major market shares and competing with previously available therapeutics.
'Histone Deacetylase (HDAC) Inhibitors Market & Pipeline Insight 2015' Report Highlights:
Histone Deacetylase (HDAC) are enzymes responsible for removal of acetyl groups present on acetyl lysine amino acid attached to histone. They are responsible for gene expression and regulation which is responsible for cellular functioning. It also helps in wrapping of histone over the Deoxyribonucleic acid (DNA). They are involved in cell growth and death which is responsible for maintaining steady state. Their involvement in diseases has been noted by investigators due to which they could serve as lead molecule for drug development. Development of HDAC based therapeutics is correlated to the development of HDAC inhibitors which have capacity to inhibit HDACs which have gone under abnormal changes. Some of the HDAC inhibitors has been successfully commercialized in global market for different ailments.
HDAC inhibitors are being developed for different malignancies and some of these products have been in global market for more than decade. New products for different diseases are being introduced in market. Most of them have been developed for oncological application while few products have been introduced in neurology category. Investigational HDAC inhibitors are being developed for HIV, autoimmune, inflammatory disease and other ailments. Potential of HDAC inhibitors in animal models for inflammatory bowel diseases, diabetes, multiple sclerosis, age related macular degeneration, cardiovascular diseases and other diseases have been shown. HDAC inhibitors clinical pipeline is becoming strong as investment in their research and development is increasing. Various products are at different stages of clinical trials which would be introduced in coming years.
HDAC inhibitor market for cancer treatment for hematological malignancies and that to for lymphoma is quite competitive. Besides, Vorinostat and Istodax there is another drug for lymphoma called Beleodaq is available in this segment. Beleodaq is a novel pan HDAC inhibitor for treatment of fast-growing type of Non-Hodgkin Lymphoma (NHL)and Peripheral T-Cell Lymphoma (PTCL). It is expected that due to similar mechanism they will offer competition to each other in coming years. Competition is also expected to be offered by monoclonal antibodies which are already known for their superior pharmacological efficacy. In this scenario, HDAC inhibitor developers have to improve drug design and pharmacological profiles in order to survive in this market segment. Their costs are somewhat lesser then monoclonal antibodies due to which patients belonging to different financial background are expected to choose them as part of their therapeutic regime.
Novel HDAC inhibitors are also being discovered by investigators but their pharmacological and commercialization potential remains elusive. Some of them are already established in global market and others are being revisited for their therapeutics efficacy in other disease segments. Hydroxamates are one of the largest segment of HDAC inhibitors which have made their niche in cancer market segment. Other categories are also being developed for different ailments due to their role in blocking different HDAC members. It could be observed that they belong to different biological groups like aliphatic acids and cyclopeptides. On the other hand, synthetic derivatives are also available which could be easily modified by chemical processes. This fact shows that investigators have plethora of choices that will help them in development of suitable pharmaceutical product having high commercialization potential. However, lots of work is required in this segment for occupying major market shares and competing with previously available therapeutics.
'Histone Deacetylase (HDAC) Inhibitors Market & Pipeline Insight 2015' Report Highlights:
- Introduction & Classification Histone Deacetylase (HDAC) Inhibitors
- Mechanism of Histone Deacetylase (HDAC) Inhibitors
- Histone Deacetylase (HDAC) Inhibitors Market Dynamics
- Global Histone Deacetylase (HDAC) Inhibitor Market Outlook
- Histone Deacetylase (HDAC) Inhibitor Clinical Pipeline by Company, Indication & Phase
- Histone Deacetylase (HDAC) Inhibitor Clinical Pipeline: 63
- Majority of Histone Deacetylase (HDAC) Inhibitor in Preclinical Phase: 35
- Marketed Histone Deacetylase (HDAC) Inhibitors: 3 (Beleodaq, Istodax & Zolinza)
1. INTRODUCTION TO HISTONE DEACETYLASE (HDAC) INHIBITORS
2. CLASSIFICATION OF HISTONE DEACETYLASE (HDAC)
2.1 Class I HDAC
2.2 Class IIa HDAC
2.3 Class IIb HDAC
2.4 Class IV HDAC
3. CLASSIFICATION OF HISTONE DEACETYLASE (HDAC) INHIBITORS
3.1 Hydroxamates
3.2 Cyclic Peptides
3.3 Aliphatic Acids
3.4 Benzamides
4. MECHANISM OF HISTONE DEACETYLASE (HDAC) INHIBITORS
5. GLOBAL HISTONE DEACETYLASE (HDAC) INHIBITOR MARKET OUTLOOK
5.1 Curent Market Scenario
5.2 Histone Deacetylase (HDAC) Pipeline Overview
6. HISTONE DEACETYLASE (HDAC) INHIBITORS MARKET DYNAMICS
6.1 Favorable Market Parameters
6.2 Commercialization Challenges
7. HISTONE DEACETYLASE (HDAC) INHIBITORS FUTURE PROSPECTS
8. HISTONE DEACETYLASE (HDAC) INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-III
8.7 Registered
9. MARKETED HISTONE DEACETYLASE (HDAC) INHIBITOR CLINICAL INSIGHT BY COMPANY & INDICATION
9.1 Belinostat (Beleodaq)
9.2 Romidepsin (Istodax)
9.3 Vorinostat (Zolinza)
10. DISCONTINUED & SUSPENDED HISTONE DEACETYLASE (HDAC) INHIBITOR CLINICAL INSIGHT
10.1 No Development Reported
10.2 Discontinued
10.3 Suspended
11. COMPETITIVE LANDSCAPE
11.1 4SC
11.2 Acetylon Pharmaceuticals
11.3 Astellas Pharma
11.4 Celleron Therapeutics
11.5 Chipscreen Biosciences
11.6 Chroma Therapeutics
11.7 Chong Kun Dang Pharmaceutical
11.8 CrystalGenomics
11.9 Curis
11.10 Digna Biotech
11.11 Evgen
11.12 Johnson & Johnson Pharmaceutical Research and Development
11.13 Italfarmaco
11.14 MEI Pharma
11.15 Mirati Therapeutics
11.16 Novartis
11.17 Onxeo
11.18 Orchid Chemicals and Pharmaceuticals
11.19 Pharmacyclics
11.20 Repligen
11.21 TetraLogic Pharmaceuticals
2. CLASSIFICATION OF HISTONE DEACETYLASE (HDAC)
2.1 Class I HDAC
2.2 Class IIa HDAC
2.3 Class IIb HDAC
2.4 Class IV HDAC
3. CLASSIFICATION OF HISTONE DEACETYLASE (HDAC) INHIBITORS
3.1 Hydroxamates
3.2 Cyclic Peptides
3.3 Aliphatic Acids
3.4 Benzamides
4. MECHANISM OF HISTONE DEACETYLASE (HDAC) INHIBITORS
5. GLOBAL HISTONE DEACETYLASE (HDAC) INHIBITOR MARKET OUTLOOK
5.1 Curent Market Scenario
5.2 Histone Deacetylase (HDAC) Pipeline Overview
6. HISTONE DEACETYLASE (HDAC) INHIBITORS MARKET DYNAMICS
6.1 Favorable Market Parameters
6.2 Commercialization Challenges
7. HISTONE DEACETYLASE (HDAC) INHIBITORS FUTURE PROSPECTS
8. HISTONE DEACETYLASE (HDAC) INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-III
8.7 Registered
9. MARKETED HISTONE DEACETYLASE (HDAC) INHIBITOR CLINICAL INSIGHT BY COMPANY & INDICATION
9.1 Belinostat (Beleodaq)
9.2 Romidepsin (Istodax)
9.3 Vorinostat (Zolinza)
10. DISCONTINUED & SUSPENDED HISTONE DEACETYLASE (HDAC) INHIBITOR CLINICAL INSIGHT
10.1 No Development Reported
10.2 Discontinued
10.3 Suspended
11. COMPETITIVE LANDSCAPE
11.1 4SC
11.2 Acetylon Pharmaceuticals
11.3 Astellas Pharma
11.4 Celleron Therapeutics
11.5 Chipscreen Biosciences
11.6 Chroma Therapeutics
11.7 Chong Kun Dang Pharmaceutical
11.8 CrystalGenomics
11.9 Curis
11.10 Digna Biotech
11.11 Evgen
11.12 Johnson & Johnson Pharmaceutical Research and Development
11.13 Italfarmaco
11.14 MEI Pharma
11.15 Mirati Therapeutics
11.16 Novartis
11.17 Onxeo
11.18 Orchid Chemicals and Pharmaceuticals
11.19 Pharmacyclics
11.20 Repligen
11.21 TetraLogic Pharmaceuticals
LIST OF FIGURES
Figure 1-1: Properties of HDAC
Figure 1-2: Therapeutic Utility of HDAC Inhibitors
Figure 1-3: Benefits of HDAC Inhibitors
Figure 1-4: Limitation of HDAC Inhibitors
Figure 2-1: Classification of HDAC
Figure 3-1: Classification of HDAC Inhibitors
Figure 4-1: Mechanism of Vorinostat
Figure 4-2: Mechanism of Panobinostat
Figure 4-3: Mechanism of Resminostat
Figure 4-4: Mechanism of Entinostat
Figure 5-1: Histone Deacetylase (HDAC) Pipeline by Phase (%), 2015
Figure 5-2: Histone Deacetylase (HDAC) Pipeline by Phase (Number), 2015
Figure 5-3: Discontinued Histone Deacetylase (HDAC) Pipeline by Phase (%), 2015
Figure 5-4: Discontinued Histone Deacetylase (HDAC) Pipeline by Phase (Number), 2015
Figure 6-1: HDAC Inhibitors Market Favorable Parameters
Figure 6-2: HDAC MarketCommercialization Challenges
Figure 11-1: 4SC Clinical Pipeline
Figure 11-2: Celleron Therapeutics Clinical Pipeline
Figure 11-3: Curis Clinical Pipeline
Figure 11-4: DIGNA Biotech Clinical Pipeline
Figure 11-5: Onxeo Clinical Pipeline
Figure 11-6: TetraLogic Pharmaceuticals Clinical Pipeline
Figure 1-1: Properties of HDAC
Figure 1-2: Therapeutic Utility of HDAC Inhibitors
Figure 1-3: Benefits of HDAC Inhibitors
Figure 1-4: Limitation of HDAC Inhibitors
Figure 2-1: Classification of HDAC
Figure 3-1: Classification of HDAC Inhibitors
Figure 4-1: Mechanism of Vorinostat
Figure 4-2: Mechanism of Panobinostat
Figure 4-3: Mechanism of Resminostat
Figure 4-4: Mechanism of Entinostat
Figure 5-1: Histone Deacetylase (HDAC) Pipeline by Phase (%), 2015
Figure 5-2: Histone Deacetylase (HDAC) Pipeline by Phase (Number), 2015
Figure 5-3: Discontinued Histone Deacetylase (HDAC) Pipeline by Phase (%), 2015
Figure 5-4: Discontinued Histone Deacetylase (HDAC) Pipeline by Phase (Number), 2015
Figure 6-1: HDAC Inhibitors Market Favorable Parameters
Figure 6-2: HDAC MarketCommercialization Challenges
Figure 11-1: 4SC Clinical Pipeline
Figure 11-2: Celleron Therapeutics Clinical Pipeline
Figure 11-3: Curis Clinical Pipeline
Figure 11-4: DIGNA Biotech Clinical Pipeline
Figure 11-5: Onxeo Clinical Pipeline
Figure 11-6: TetraLogic Pharmaceuticals Clinical Pipeline
LIST OF TABLES
Table 1-1: Few Important HDACi under Development for Different Indications
Table 3-1: HDAC Inhibitors Belonging to Different Classes
Table 4-1: FDA Approved HDACi for Lymphoma
Table 1-1: Few Important HDACi under Development for Different Indications
Table 3-1: HDAC Inhibitors Belonging to Different Classes
Table 4-1: FDA Approved HDACi for Lymphoma
